Ken Maes

2.0k total citations
50 papers, 1.5k citations indexed

About

Ken Maes is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Ken Maes has authored 50 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Molecular Biology, 28 papers in Hematology and 13 papers in Oncology. Recurrent topics in Ken Maes's work include Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (12 papers) and Histone Deacetylase Inhibitors Research (12 papers). Ken Maes is often cited by papers focused on Multiple Myeloma Research and Treatments (25 papers), Protein Degradation and Inhibitors (12 papers) and Histone Deacetylase Inhibitors Research (12 papers). Ken Maes collaborates with scholars based in Belgium, France and Sweden. Ken Maes's co-authors include Karin Vanderkerken, Elke De Bruyne, Eline Menu, Kim De Veirman, Els Van Valckenborgh, Nathan De Beule, Jinheng Wang, Rik Schots, Hendrik De Raeve and Sylvia Faict and has published in prestigious journals such as Blood, Cancer Research and Scientific Reports.

In The Last Decade

Ken Maes

49 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ken Maes Belgium 23 1.0k 643 396 345 265 50 1.5k
Yu-Tzu Tai United States 13 1.2k 1.2× 632 1.0× 565 1.4× 428 1.2× 382 1.4× 19 1.8k
Fotis Asimakopoulos United States 20 538 0.5× 443 0.7× 557 1.4× 194 0.6× 333 1.3× 40 1.3k
Karène Mahtouk France 18 831 0.8× 833 1.3× 528 1.3× 191 0.6× 290 1.1× 34 1.5k
Marc Hotfilder Germany 19 695 0.7× 224 0.3× 389 1.0× 254 0.7× 217 0.8× 40 1.3k
Marina Bolzoni Italy 19 562 0.5× 635 1.0× 610 1.5× 137 0.4× 164 0.6× 51 1.2k
Teruyuki Muraguchi Japan 11 748 0.7× 348 0.5× 326 0.8× 235 0.7× 123 0.5× 11 1.2k
Marcus M. Schittenhelm Germany 16 604 0.6× 767 1.2× 362 0.9× 179 0.5× 252 1.0× 42 1.5k
Denise Toscani Italy 18 571 0.6× 570 0.9× 557 1.4× 147 0.4× 199 0.8× 48 1.2k
Lara Tickenbrock Germany 18 1.0k 1.0× 715 1.1× 229 0.6× 138 0.4× 189 0.7× 28 1.5k
Monica Minischetti Italy 7 615 0.6× 530 0.8× 471 1.2× 238 0.7× 63 0.2× 8 1.1k

Countries citing papers authored by Ken Maes

Since Specialization
Citations

This map shows the geographic impact of Ken Maes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Maes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Maes more than expected).

Fields of papers citing papers by Ken Maes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ken Maes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Maes. The network helps show where Ken Maes may publish in the future.

Co-authorship network of co-authors of Ken Maes

This figure shows the co-authorship network connecting the top 25 collaborators of Ken Maes. A scholar is included among the top collaborators of Ken Maes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Maes. Ken Maes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Beck, Susanne, Vladimı́r Beneš, Hans Salwender, et al.. (2023). RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Frontiers in Immunology. 14. 1286700–1286700. 3 indexed citations
2.
Fan, Rong, Philip Vlummens, Anke Maes, et al.. (2023). Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma. Journal for ImmunoTherapy of Cancer. 11(1). e005319–e005319. 12 indexed citations
3.
Awad, Robin Maximilian, Veronica Basso, Noëlia Casares, et al.. (2022). Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. Frontiers in Immunology. 13. 7 indexed citations
4.
Fan, Rong, Nathan De Beule, Anke Maes, et al.. (2022). The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers. Frontiers in Immunology. 13. 1016059–1016059. 15 indexed citations
5.
Becker, Ann De, et al.. (2022). Genetic profiling of human bone marrow mesenchymal stromal cells after in vitro expansion in clinical grade human platelet lysate. Frontiers in Bioengineering and Biotechnology. 10. 1008271–1008271. 3 indexed citations
6.
Vlummens, Philip, Stefaan Verhulst, Kim De Veirman, et al.. (2022). Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach. Frontiers in Cell and Developmental Biology. 10. 879057–879057. 5 indexed citations
7.
Maes, Ken, Anna Mondino, Juan José Lasarte, et al.. (2021). Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. Frontiers in Immunology. 12. 652160–652160. 16 indexed citations
8.
Dekempeneer, Yana, Vicky Caveliers, Maarten Ooms, et al.. (2020). Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer. Molecular Pharmaceutics. 17(9). 3553–3566. 45 indexed citations
9.
Vlummens, Philip, Kim De Veirman, Eline Menu, et al.. (2019). The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma. Frontiers in Genetics. 10. 740–740. 5 indexed citations
10.
Maes, Anke, Ken Maes, Philip Vlummens, et al.. (2019). Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma. Blood Cancer Journal. 9(12). 87–87. 11 indexed citations
11.
Maes, Anke, Ken Maes, Hendrik De Raeve, et al.. (2019). The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma. British Journal of Cancer. 120(12). 1137–1146. 12 indexed citations
12.
Veirman, Kim De, Eline Menu, Ken Maes, et al.. (2018). Myeloid-derived suppressor cells induce multiple myeloma cell survival by activating the AMPK pathway. Cancer Letters. 442. 233–241. 48 indexed citations
13.
Faict, Sylvia, Joséphine Muller, Kim De Veirman, et al.. (2018). Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer Journal. 8(11). 105–105. 125 indexed citations
14.
Smedt, Eva De, Hui Lui, Ken Maes, et al.. (2018). The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response. Frontiers in Oncology. 8. 566–566. 42 indexed citations
15.
Bruyer, Angélique, Ken Maes, Laurie Herviou, et al.. (2018). DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. British Journal of Cancer. 118(8). 1062–1073. 32 indexed citations
16.
Veirman, Kim De, Nathan De Beule, Ken Maes, et al.. (2017). Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunology Research. 5(10). 839–846. 44 indexed citations
17.
Smedt, Eva De, Ken Maes, Stefaan Verhulst, et al.. (2017). Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. Cancer Research. 78(5). 1155–1168. 30 indexed citations
18.
Menu, Eline, Djoere Gaublomme, Karin Vanderkerken, et al.. (2017). Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma. Leukemia. 31(12). 2678–2685. 29 indexed citations
19.
Veirman, Kim De, Jinheng Wang, Song Xu, et al.. (2016). Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity. Cancer Letters. 377(1). 17–24. 111 indexed citations
20.
Maes, Ken, Miguel Lemaire, Jordan Gauthier, et al.. (2012). The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Blood. 120(21). 1833–1833. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu-Tzu Tai Breakdown of academic impact, for papers by Fotis Asimakopoulos Breakdown of academic impact, for papers by Karène Mahtouk Breakdown of academic impact, for papers by Marc Hotfilder Breakdown of academic impact, for papers by Marina Bolzoni Breakdown of academic impact, for papers by Teruyuki Muraguchi Breakdown of academic impact, for papers by Marcus M. Schittenhelm Breakdown of academic impact, for papers by Denise Toscani Breakdown of academic impact, for papers by Lara Tickenbrock Breakdown of academic impact, for papers by Monica Minischetti
Rankless by CCL
2026